1. Home
  2. LFVN vs GLSI Comparison

LFVN vs GLSI Comparison

Compare LFVN & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LFVN
  • GLSI
  • Stock Information
  • Founded
  • LFVN N/A
  • GLSI 2006
  • Country
  • LFVN United States
  • GLSI United States
  • Employees
  • LFVN N/A
  • GLSI N/A
  • Industry
  • LFVN Biotechnology: Pharmaceutical Preparations
  • GLSI Biotechnology: Pharmaceutical Preparations
  • Sector
  • LFVN Health Care
  • GLSI Health Care
  • Exchange
  • LFVN Nasdaq
  • GLSI Nasdaq
  • Market Cap
  • LFVN 145.2M
  • GLSI 149.5M
  • IPO Year
  • LFVN N/A
  • GLSI 2020
  • Fundamental
  • Price
  • LFVN $10.90
  • GLSI $11.54
  • Analyst Decision
  • LFVN Strong Buy
  • GLSI Strong Buy
  • Analyst Count
  • LFVN 2
  • GLSI 1
  • Target Price
  • LFVN $30.50
  • GLSI $39.00
  • AVG Volume (30 Days)
  • LFVN 165.6K
  • GLSI 63.0K
  • Earning Date
  • LFVN 10-28-2025
  • GLSI 11-13-2025
  • Dividend Yield
  • LFVN 1.65%
  • GLSI N/A
  • EPS Growth
  • LFVN 226.09
  • GLSI N/A
  • EPS
  • LFVN 0.75
  • GLSI N/A
  • Revenue
  • LFVN $228,530,000.00
  • GLSI N/A
  • Revenue This Year
  • LFVN $8.75
  • GLSI N/A
  • Revenue Next Year
  • LFVN N/A
  • GLSI N/A
  • P/E Ratio
  • LFVN $14.51
  • GLSI N/A
  • Revenue Growth
  • LFVN 14.17
  • GLSI N/A
  • 52 Week Low
  • LFVN $9.83
  • GLSI $8.06
  • 52 Week High
  • LFVN $27.38
  • GLSI $15.50
  • Technical
  • Relative Strength Index (RSI)
  • LFVN 36.63
  • GLSI 51.72
  • Support Level
  • LFVN $10.39
  • GLSI $11.03
  • Resistance Level
  • LFVN $12.10
  • GLSI $11.90
  • Average True Range (ATR)
  • LFVN 0.86
  • GLSI 0.69
  • MACD
  • LFVN -0.18
  • GLSI -0.01
  • Stochastic Oscillator
  • LFVN 15.08
  • GLSI 39.42

About LFVN Lifevantage Corporation (Delaware)

Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: